Oct 30 (Reuters) - Diagnostics firm Bio-Rad Laboratories (BIO.N), opens new tab posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical ...

Bio-Rad is an established Fortune 1000 biotech company that creates products that help people live longer, healthier lives. Bio-Rad’s Digital Biology Group (DBG) in Pleasanton makes products ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...

Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a ...

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Reporting.” A reconciliation ...

Bio-Rad Laboratories (BIO) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...